Established therapies and novel targets in the treatment of Parkinson's disease

Livia Dézsi, László Vécsei

Research output: Contribution to journalReview article

3 Citations (Scopus)


Parkinson's disease affects more than 1% of individuals older than 60 years of age. The gold standard of its symptomatic treatment is levodopa therapy, which in time leads to motor fluctuations and dyskinesia due to noncontinuous receptor stimulation. Dopamine agonists and monoamine oxidase-B inhibitors are recommended as initial therapy, but they are less effective in the advanced stages of the disease. Treatment should be individualized for the patient, dependent on the stage, with attention to nonmotor symptoms. No effective neuroprotective therapy for Parkinson's disease is yet available, and there is currently substantial interest in the development of new nondopaminergic agents. Analogs of kynurenic acid and inhibitors of the enzymes involved in the synthesis of quinolinic acid may exert a neuroprotective effect.

Original languageEnglish
Pages (from-to)631-644
Number of pages14
JournalExpert Review of Clinical Pharmacology
Issue number6
Publication statusPublished - Dec 1 2009


  • Continuous stimulation
  • Dopamine agonist
  • Dyskinesia
  • Kynurenines
  • Levodopa
  • MAO-B inhibitor
  • Parkinson's disease

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Established therapies and novel targets in the treatment of Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this